GlaxoSmithKline

The article explores the moral crisis in healthcare, questioning the distinction between killing and letting die in a profit-driven system. It recounts personal experiences with corporate corruption in the pharmaceutical industry and discusses how modern bureaucracies perpetuate harm through detachment and specialization, echoing Hannah Arendt's concept of the banality of evil. The piece critiques the healthcare and pharmaceutical industries for prioritizing profit over patient care, and calls for a reimagining of healthcare as a collective responsibility.

GSK's First-Engot-OV44 phase III trial of niraparib (Zejula) and dostarlimab (Jemperli) met primary endpoint of progression free survival but not key secondary endpoint of overall survival. Further analyses ongoing.

The 'Meningitis - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of meningitis clinical trials, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, providing insights into global clinical trials landscape and enrollment trends.

GSK announced significant PFS improvement with dostarlimab added to platinum-based chemotherapy and niraparib maintenance in advanced ovarian cancer, per FIRST-ENGOT-OV44 trial. OS did not meet statistical significance; safety profile consistent with individual agents.

Ionis Pharmaceuticals' shares rose 5% after FDA approved its RNA-targeted therapy, Tryngolza, for familial chylomicronemia syndrome (FCS), marking the first treatment for FCS in the U.S. The approval is supported by phase III BALANCE study results showing significant triglyceride-lowering and reduced acute pancreatitis attacks. Tryngolza is Ionis' first wholly-owned drug and independent commercial launch, expected by year-end. The company is also evaluating Tryngolza for severe hypertriglyceridemia and has collaborations with major drugmakers for various treatments.

The Pediatric Clinical Trials Market is projected to grow from US$ 20.1 Billion in 2023 to US$ 33.0 Billion by 2033, with a CAGR of 5.0%. North America led in 2023 with a 39.10% share. Challenges include ethical concerns, limited recruitment, and high costs. Innovations like adaptive trials and digital technologies are enhancing efficiency.

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK) with a £16.90 price target. GSK shares closed at £1,321.50. Analyst consensus suggests a Hold rating with a £1,628.00 average price target, implying a 23.19% upside. Deutsche Bank also maintained a Hold rating with a £13.50 target. GSK has a market cap of £54.43B and a P/E ratio of 21.63. Corporate insider sentiment is positive.

GSK's FIRST trial met its primary endpoint of progression-free survival in first-line advanced ovarian cancer with the addition of Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab.